JP5658688B2 - カルボキサミド化合物およびその使用方法 - Google Patents

カルボキサミド化合物およびその使用方法 Download PDF

Info

Publication number
JP5658688B2
JP5658688B2 JP2011548297A JP2011548297A JP5658688B2 JP 5658688 B2 JP5658688 B2 JP 5658688B2 JP 2011548297 A JP2011548297 A JP 2011548297A JP 2011548297 A JP2011548297 A JP 2011548297A JP 5658688 B2 JP5658688 B2 JP 5658688B2
Authority
JP
Japan
Prior art keywords
alkyl
haloalkyl
substituted
containing group
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011548297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012516349A5 (cg-RX-API-DMAC7.html
JP2012516349A (ja
Inventor
イーハブ エス. ダルウィッシュ
イーハブ エス. ダルウィッシュ
ホイ ホン
ホイ ホン
ラジンデル シング
ラジンデル シング
シャン スー
シャン スー
Original Assignee
ライジェル ファーマシューティカルズ, インコーポレイテッド
ライジェル ファーマシューティカルズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライジェル ファーマシューティカルズ, インコーポレイテッド, ライジェル ファーマシューティカルズ, インコーポレイテッド filed Critical ライジェル ファーマシューティカルズ, インコーポレイテッド
Publication of JP2012516349A publication Critical patent/JP2012516349A/ja
Publication of JP2012516349A5 publication Critical patent/JP2012516349A5/ja
Application granted granted Critical
Publication of JP5658688B2 publication Critical patent/JP5658688B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N61/00—Biocides, pest repellants or attractants, or plant growth regulators containing substances of unknown or undetermined composition, e.g. substances characterised only by the mode of action
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Emergency Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2011548297A 2009-01-28 2010-01-28 カルボキサミド化合物およびその使用方法 Expired - Fee Related JP5658688B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14798209P 2009-01-28 2009-01-28
US61/147,982 2009-01-28
PCT/US2010/022411 WO2010088392A1 (en) 2009-01-28 2010-01-28 Carboxamide compounds and methods for using the same

Publications (3)

Publication Number Publication Date
JP2012516349A JP2012516349A (ja) 2012-07-19
JP2012516349A5 JP2012516349A5 (cg-RX-API-DMAC7.html) 2013-03-14
JP5658688B2 true JP5658688B2 (ja) 2015-01-28

Family

ID=42061132

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011548297A Expired - Fee Related JP5658688B2 (ja) 2009-01-28 2010-01-28 カルボキサミド化合物およびその使用方法

Country Status (17)

Country Link
US (2) US8362235B2 (cg-RX-API-DMAC7.html)
EP (1) EP2391616B1 (cg-RX-API-DMAC7.html)
JP (1) JP5658688B2 (cg-RX-API-DMAC7.html)
KR (1) KR101693061B1 (cg-RX-API-DMAC7.html)
CN (1) CN102365275B (cg-RX-API-DMAC7.html)
AU (1) AU2010208247B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1007287B8 (cg-RX-API-DMAC7.html)
CA (1) CA2750835C (cg-RX-API-DMAC7.html)
EA (1) EA022083B1 (cg-RX-API-DMAC7.html)
ES (1) ES2581678T3 (cg-RX-API-DMAC7.html)
IL (1) IL214203A (cg-RX-API-DMAC7.html)
MX (1) MX2011007639A (cg-RX-API-DMAC7.html)
NZ (1) NZ594556A (cg-RX-API-DMAC7.html)
SG (1) SG172974A1 (cg-RX-API-DMAC7.html)
UA (1) UA106600C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010088392A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201105215B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013532692A (ja) * 2010-07-29 2013-08-19 ライジェル ファーマシューティカルズ, インコーポレイテッド Ampk活性化複素環化合物およびその使用方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009132136A1 (en) 2008-04-23 2009-10-29 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
US8796254B2 (en) 2010-03-31 2014-08-05 Rigel Pharmaceuticals, Inc. Methods for using carboxamide, sulfonamide and amine compounds
US9005909B2 (en) 2011-01-06 2015-04-14 Rigel Pharmaceuticals, Inc. Whole blood assay for measuring AMPK activation
US9409884B2 (en) 2012-02-01 2016-08-09 Rigel Pharmaceuticals, Inc. 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ampkを活性化させるインダゾール化合物
US20150087673A1 (en) * 2013-09-26 2015-03-26 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
US20160214967A1 (en) 2013-09-30 2016-07-28 The University Of Tokyo Activator of adiponectin receptor
EP3737361A4 (en) 2018-01-11 2021-08-25 Centaurus Therapeutics INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR THE TREATMENT OF DISEASES
US12194023B2 (en) 2018-11-29 2025-01-14 The Research Foundation For The State University Of New York Compositions and methods for modular control of bioorthogonal ligation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
KR100579792B1 (ko) 1998-05-13 2006-05-12 동화약품공업주식회사 신규 2,5-피리딘디카복실산 유도체
AU2001287898A1 (en) * 2000-09-22 2002-04-02 Stephen Garland Pyrazolopyridines and pyrazolopyridazines as antidiabetics
TW200503994A (en) * 2003-01-24 2005-02-01 Novartis Ag Organic compounds
CA2634235A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
DE602006021591D1 (de) 2006-12-11 2011-06-09 Genetics Co Inc Aromatische 1,4-DI-Carboxylamide und deren Verwendung
ES2627221T3 (es) * 2006-12-28 2017-07-27 Rigel Pharmaceuticals, Inc. Compuestos de heterocicloalquiloxibenzamida N-sustituidos y métodos de uso
GB0706793D0 (en) * 2007-04-05 2007-05-16 Evotec Ag Compounds
EP2231600B1 (en) 2007-11-16 2015-07-29 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
EP2231666B1 (en) * 2007-12-12 2015-07-29 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
WO2009132136A1 (en) * 2008-04-23 2009-10-29 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
US8796254B2 (en) 2010-03-31 2014-08-05 Rigel Pharmaceuticals, Inc. Methods for using carboxamide, sulfonamide and amine compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013532692A (ja) * 2010-07-29 2013-08-19 ライジェル ファーマシューティカルズ, インコーポレイテッド Ampk活性化複素環化合物およびその使用方法

Also Published As

Publication number Publication date
SG172974A1 (en) 2011-08-29
ES2581678T3 (es) 2016-09-06
US20130131078A1 (en) 2013-05-23
KR20110119755A (ko) 2011-11-02
US8362235B2 (en) 2013-01-29
EA201170979A1 (ru) 2012-02-28
EP2391616A1 (en) 2011-12-07
IL214203A (en) 2015-01-29
CA2750835C (en) 2018-09-04
HK1164860A1 (zh) 2012-09-28
NZ594556A (en) 2013-11-29
CA2750835A1 (en) 2010-08-05
IL214203A0 (en) 2011-08-31
ZA201105215B (en) 2012-09-26
CN102365275A (zh) 2012-02-29
JP2012516349A (ja) 2012-07-19
EP2391616B1 (en) 2016-03-30
BRPI1007287B1 (pt) 2021-03-09
KR101693061B1 (ko) 2017-01-04
WO2010088392A1 (en) 2010-08-05
MX2011007639A (es) 2011-09-15
AU2010208247A1 (en) 2011-08-11
EA022083B1 (ru) 2015-10-30
UA106600C2 (uk) 2014-09-25
US8846600B2 (en) 2014-09-30
AU2010208247B2 (en) 2015-06-18
US20100190802A1 (en) 2010-07-29
CN102365275B (zh) 2014-09-24
BRPI1007287B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
CN102365275B (zh) 羧酰胺化合物及其使用方法
EP2598483B1 (en) Ampk-activating heterocyclic compounds and methods for using the same
JP5650404B2 (ja) N−置換−ヘテロシクロアルキルオキシベンズアミド化合物およびその使用方法
EP2276761B1 (en) Carboxamide compounds for the treatment of metabolic disorders
AU2008322426B2 (en) Carboxamide, sulfonamide and amine compounds for metabolic disorders
CA2906086A1 (en) Inhibitors of leukotriene a4 hydrolase
JP2011506480A (ja) 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物
WO2011123681A1 (en) Methods for using carboxamide, sulfonamide and amine compounds
EP3500558B1 (en) Benzimidazole direct ampk activators
HK1164860B (en) Carboxamide compounds and methods for using the same
HK1152939B (en) Carboxamide compounds for the treatment of metabolic disorders
HK1148525B (en) Carboxamide, sulfonamide and amine compounds for metabolic disorders
HK1148524B (en) Carboxamide, sulfonamide and amine compounds for metabolic disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130122

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140320

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140624

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141128

R150 Certificate of patent or registration of utility model

Ref document number: 5658688

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees